What is LL-37 peptide? LL-37 is a human cathelicidin peptide containing 37 amino acid residues. It is generated from a larger precursor called hCAP-18. Scientists study its involvement in antimicrobial activity, immune cell communication, and wound biology, using experiments that range from isolated cells to clinical trials. [1] [2]
These different types of evidence should be read separately. A cell response, a change in a wound measurement, and an effect in a person are different findings. Understanding the experimental setting makes LL-37 descriptions more useful and less confusing.
This article provides scientific context alongside Azzurri's LL-37 product page. It focuses on the molecule and selected published studies, including findings that did not confirm an overall benefit.
Where does LL-37 come from?
LL-37 is produced by processing a larger protein. A 2001 study investigated how human hCAP-18 is cleaved to release LL-37. In material released by neutrophils, the researchers identified proteinase 3 as the enzyme responsible for this processing. [1]
This distinction between a precursor and its peptide fragment matters. Measuring the larger protein is not necessarily the same as measuring the released peptide. A description that uses both names interchangeably can obscure what an experiment actually detected.
When reading a paper, look for the molecule the investigators measured and the method they used. Those details help establish whether two apparently similar findings can be compared.
How is LL-37 involved in immune signaling?
LL-37 is often discussed as an antimicrobial peptide, but its experimental effects extend beyond direct interaction with microbes. A 2000 study examined its ability to attract human immune cells. The investigators linked this movement to a receptor then called FPRL1. [2]
This movement toward a chemical signal is called chemotaxis. The experiments examined particular cells and receptor responses. They did not measure whether a person became less likely to develop an infection.
That distinction is useful when interpreting phrases such as immune support. A measurable immune response does not automatically establish a beneficial change in overall immune function.
Azzurri's introduction to antimicrobial peptides provides broader background on the family. LL-37 requires its own evidence because findings about one peptide cannot automatically be assigned to another.
Why does the exact LL-37 structure matter?
A study published online in 2024 examined LL-37 and autophagy, a cellular process involved in handling and recycling intracellular material. In human macrophage experiments, changes at the peptide's beginning altered whether the tested preparations initiated that process. The initial pair of leucine residues was important in this experimental system. [3]
The work illustrates a specific principle: small chemical differences can change a measured response. It does not establish that changing autophagy in these cells produces a general health benefit.
Azzurri's guide to peptide sequence and biological activity explains the broader connection between structure and function. For any particular claim, the exact tested structure still matters.
What did the early LL-37 wound study find?
A 2014 randomized, placebo-controlled trial enrolled 34 people with difficult-to-close venous leg ulcers. The investigators examined topical LL-37 preparations and followed wound measurements over time. Some tested groups showed encouraging changes, while the highest tested concentration did not outperform placebo. [4]
This was an early clinical signal with a small participant group. It supported further investigation, but it could not establish that every LL-37 preparation would produce the same result.
When reading an early trial, keep three questions together: who participated, what preparation was tested, and which outcome improved? Leaving out any one of these can make a limited finding appear much broader.
What happened in the larger LL-37 clinical trial?
The 2021 HEAL LL-37 trial enrolled 148 patients with hard-to-close venous leg ulcers. It was a randomized, double-blind, placebo-controlled study of topical preparations used alongside compression care. Across the full study population, the investigators did not find a statistically significant improvement in wound closure outcomes compared with placebo. [5]
A later subgroup analysis suggested a possible signal among participants with larger wounds. Because this was a post hoc analysis, it required confirmation in a study designed to test that question.
Post hoc means the analysis followed examination of the study data. Such analyses can help generate a useful next question, but they do not replace the overall trial result.
The early and larger studies belong in the same discussion. Selecting only the encouraging result would give readers an incomplete account of the clinical evidence.
Why does the formulation matter when comparing LL-37 studies?
Not every investigation bearing the LL-37 name tests the same kind of preparation. For example, a 2023 study involving 238 hospitalized adults examined an oral preparation based on recombinant Lactococcus lactis, a bacterium engineered to produce LL-37. The study was open-label and focused on the timing of negative viral RNA tests in a particular infection setting. [6]
That formulation differs from a topical preparation or an isolated peptide product. The shared peptide name does not establish that their exposure or effects are interchangeable.
The relevant question is not simply whether human studies exist. It is whether a study used the preparation, population, and endpoint needed to support the specific statement being made.
What can stability experiments tell us?
A 2011 experiment examined synthetic LL-37 alongside selected enzymes and wound fluid samples from nine venous leg ulcers. Under the tested conditions, one enzyme degraded the peptide, another did not, and the wound fluid altered its susceptibility to breakdown. [7]
This was a laboratory investigation of a biological environment. It was not a storage study establishing a shelf life for a finished product.
The distinction prevents a common reasoning error. Stability in a particular experiment cannot be converted into a universal storage period, and intact peptide in a sample does not by itself prove a clinical effect.
What do these findings mean for safety?
The wound trials assessed tolerability under their defined clinical conditions. Their safety observations should remain attached to the preparations, participants, and follow-up periods studied. They cannot establish safety for a different route or prolonged exposure. [4] [5]
A naturally occurring molecule is not automatically suitable for unrestricted external use. Its normal biological presence and the effects of a manufactured preparation are separate questions.
Someone dealing with a persistent wound or possible infection needs clinical assessment. These studies do not provide a basis for replacing established care or designing a personal regimen.
How to read an LL-37 product description alongside the evidence
Start with the complete compound identity. Then check whether the cited evidence concerns isolated cells, an animal model, a laboratory sample, or people. Finally, compare the tested formulation with the product being described.
A statement about cell movement should remain a statement about cell movement. An observation in a specific patient subgroup should retain that qualifier. Clear language keeps the evidence useful without enlarging the conclusion.
The Azzurri LL-37 listing provides the product reference point. Analytical documentation and published clinical findings answer different questions. Identifying a peptide does not demonstrate that a finished product reproduces an outcome from a clinical trial.
Study sources
- Sørensen and colleagues, 2001. Processing of hCAP-18 by proteinase 3. PubMed, PMID 11389039.
- Yang and colleagues, 2000. LL-37, immune cell migration, and receptor signaling. PubMed, PMID 11015447.
- LL-37 structural modifications and autophagy in human macrophages, published online 2024. PubMed, PMID 39708316.
- Grönberg and colleagues, 2014. Early randomized LL-37 trial in venous leg ulcers. PubMed, PMID 25041740.
- Mahlapuu and colleagues, 2021. Multicenter LL-37 trial in venous leg ulcers. PubMed, PMID 34687253.
- Zhao and colleagues, 2023. Oral LL-37 formulation and viral RNA outcomes in hospitalized adults. PubMed, PMID 37605995.
- Laboratory investigation of LL-37 stability in wound fluid, 2011. PubMed, PMID 21547341.
Frequently asked questions
What is LL-37 peptide?
It is a 37-residue human cathelicidin peptide generated from hCAP-18. Studies examine its antimicrobial activity, cell signaling, and behavior in specific clinical settings.
Is LL-37 the same as hCAP-18?
No. hCAP-18 is the larger precursor. LL-37 is a peptide released through processing of that precursor, so the names describe different molecular forms.
Have LL-37 human studies been published?
Yes. Examples include venous leg ulcer trials and an investigation of an engineered oral formulation. Each study needs to be interpreted according to its own preparation and endpoints.
Did the larger wound trial show an overall benefit?
No statistically significant improvement was found across the full population. A subgroup observation required further study and should not be presented as the overall result. [5]
Does antimicrobial activity mean LL-37 can replace infection care?
No. Experimental antimicrobial activity does not establish an appropriate clinical option for an individual. A suspected infection requires assessment by a qualified healthcare professional.
Can findings from one LL-37 preparation be applied to another?
Not automatically. Molecular identity, formulation, route, study population, and outcome all affect whether a comparison is valid. A shared name alone is insufficient.